Imbruvica Shows Response in 2/3 of Steroid Dependent, Refractory cGVHD Patients in Phase II Study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In a phase II study, ibrutinib (Imbruvica) demonstrated clinically meaningful and durable responses and reduced symptom severity, with an overall response rate of 67% in patients with cGVHD.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Nadeem R. Abu-RustumLouis Burt NaborsMichael J. StylerJames ThompsonErin HeslerNadeem R. Abu-Rustum, Louis Burt Nabors, Michael J. Styler, and James Thompson were recognized by the National Comprehensive Cancer Network as its 2025 awardees who “go above and beyond to define and advance quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives.”

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login